Bart Lambrecht (VIB-UGent Center for Inflammation research) has taken the lead in several clinical trials that are running under the promotorship of University Hospital Ghent across Belgium, in partnership with VIB. Some trials repurpose existing drugs to treat patients infected with COVID-19. A first trial is evaluating the effect of inhaled Leukine® on lung function and patient outcomes. A second approach focuses on several existing rheumatism medications to alleviate the excessive inflammatory reaction in severely affected COVID-19 patients. Two other trials employ new drugs to target the pro-inflammatory and pro-coagulant complement system.
Every five years, the Research Foundation Flanders (FWO) awards the prestigious Excellence Prizes to eminent Flemish researchers with a distinguished career in science. In 2020, two VIB researchers working at Ghent University have received this important recognition for their outstanding scientific career and dedication to research: Prof. Bart Lambrecht (VIB-UGent Center for Inflammation Research) and prof. Wout Boerjan (VIB-UGent Center for Plant Systems Biology).
With a discovery that could rewrite the immunology textbooks, an international group of scientists, including the teams of Bart Lambrecht, Martin Guilliams, Hamida Hammad, and Charlotte Scott (all from the VIB-UGent Center for Inflammation Research) identified a new type of antigen-presenting immune cell.
Studie van UZ Gent, Federaal Kennis Centrum voor Gezondheidszorg (KCE) en VIB. Vandaag start in negen Belgische centra een studie met bestaande medicatie die gebruikt wordt bij de behandeling van reuma. De studie zal onderzoeken of de medicatie erin slaagt om een overmatige ontstekingsreactie bij een COVID-19-infectie af te remmen en zo de longschade te beperken.
University Hospital Ghent and VIB are assessing a drug called Leukine® to treat patients with respiratory illness associated with COVID-19. Major medical centers in Germany and Italy are considering joining the study. The study will evaluate the effect of Leukine® on lung function and patient outcomes.
Belgian research groups from the VIB, Ghent University, Ghent University Hospital, and the biotech company argenx have solved a century-long puzzle about the presence of protein crystals in asthma. Normally, proteins do not crystallize in the body, but there are some instances where this process does occur.
The VIB Grand Challenges Program is a translational research program with which we aim to significantly increase the societal impact of VIB. We are convinced that this can be done by teaming up with experts outside VIB who have complementary expertise (clinic, agriculture, engineering …). Together we can exploit our knowledge, expertise and toolbox to generate new, otherwise untapped avenues to create added value for society. Three projects were selected and will receive funding up to 2.5 M€. We look forward to the outcome of these collaborations!
Prof. Bart Lambrecht (VIB-UGent Center for Inflammation Research) is awarded an Advanced Grant. To qualify, a scientist has to be able to prove exceptional leadership and a solid track record of significant research achievements over at least 10 years. To leverage their impact, individual ERC grants provide considerable amounts of money, up to €2,5million for an Advanced Grant, for example. With a budget like that, researchers can embark on a dream project that would otherwise remain out of reach.
Scientists from VIB-UGent have discovered insights for a possible new therapy for eczema that also reduces the severity of asthma. The findings are an important next step in understanding the relationship between the two inflammatory diseases and to developing effective therapies. The results of the study are published in the Journal of Investigative Dermatology.
Almost everyone knows someone with asthma. An international research consortium for asthma prevention led by the Dutch scientist Hermelijn Smits will search for novel approaches to prevent, potentially eliminate, this lung disease in the world. They will focus on the exploitation of commensals: ‘beneficial’ micro-organisms that live in and around our body.